Skip to main content
SpringerLink
Log in

Can Animal Models Help Us Select Specific Compounds for Cancer Prevention Trials?

  • Conference paper
Tumor Prevention and Genetics III

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 166))

Abstract

Animal models provide unparalleled mechanistic insights into cancer development and potential opportunity for cancer prevention. Nevertheless, species differ markedly with regard to dietary exposures, cancer development, drug effects, and toxicity thresholds; therefore, testing in a single animal system may not predict human responses. Although replication of human cancer in animal models remains inexact, more than two decades of research have clearly yielded significant gains, as is evident in agents tested—and in certain cases, approved—for the prevention of epithelial cancers. Research efficiencies achievable through preliminary testing in genetically engineered and carcinogen-induced animal models enable us to probe genetic and signaling pathways that drive normal and neoplastic processes, and thereby figure prominently in decision trees for agent development.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [No authors listed] (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330:1029–1035

    Google Scholar 

  2. Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB, Sporn MB (1996) Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 88:123–125

    PubMed  CAS  Google Scholar 

  3. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891–899

    Article  PubMed  CAS  Google Scholar 

  4. Beaty MM, Lee EY, Glauert HP (1993) Influence of dietary calcium and vitamin D on colon epithelial cell proliferation and 1,2-dimethylhydrazine-induced colon carcinogenesis in rats fed high fat diets. J Nutr 123:144–152

    PubMed  CAS  Google Scholar 

  5. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, Couturier D, Coste T, Little J, Chaussade S (2003) Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125:328–336

    Article  PubMed  CAS  Google Scholar 

  6. Bostwick DG, Ramnani D, Qian J (2000) Prostatic intraepithelial neoplasia: animal models 2000. Prostate 43:286–294

    Article  PubMed  CAS  Google Scholar 

  7. Brodie AM, Garrett WM, Hendrickson JR, Tsai-Morris CH (1982) Effects of aromatase inhibitor 4-hydroxyandrostenedione and other compounds in the 7, 12-dimethylbenz(a)anthracene-induced breast carcinoma model. Cancer Res 42:3360s–3364s

    PubMed  CAS  Google Scholar 

  8. Castonguay A, Pepin P, Stoner GD (1991) Lung tumorigenicity of NNK given orally to A/J mice: its application to chemopreventive efficacy studies. Exp Lung Res 17:485–499

    Article  PubMed  CAS  Google Scholar 

  9. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125–134

    Article  PubMed  CAS  Google Scholar 

  10. Conaway CC, Jiao D, Kelloff GJ, Steele VE, Rivenson A, Chung FL (1998) Chemopreventive potential of fumaric acid, N-acetylcysteine, N-(4-hydroxyphenyl) retinamide and beta-carotene for tobacco-nitrosamine-induced lung tumors in A/J mice. Cancer Lett 124: 85–93

    Article  PubMed  CAS  Google Scholar 

  11. Cone MV, Nettesheim P (1973) Effects of vitamin A on 3-methylcholanthrene-induced squamous metaplasias and early tumors in the respiratory tract of rats. J Natl Cancer Inst 50:1599–1606

    PubMed  CAS  Google Scholar 

  12. Corpet DE, Pierre F (2003) Point: from animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 12:391–400

    PubMed  Google Scholar 

  13. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197

    PubMed  CAS  Google Scholar 

  14. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T; IBIS investigators (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360:817–824

    PubMed  CAS  Google Scholar 

  15. Esmat AY, Refaie FM, Shaheen MH, Said MM (2002) Chemoprevention of prostate carcinogenesis by DFMO and/or finasteride treatment in male Wistar rats. Tumori 88:513–521

    PubMed  CAS  Google Scholar 

  16. Fischer SM, Conti CJ, Viner J, Aldaz CM, Lubet RA (2003) Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Carcinogenesis 24: 945–952

    Article  PubMed  CAS  Google Scholar 

  17. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388

    Article  PubMed  CAS  Google Scholar 

  18. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316

    Article  PubMed  CAS  Google Scholar 

  19. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802

    Article  PubMed  CAS  Google Scholar 

  20. Gottardis MM, Jordan VC (1987) Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47:4020–4024

    PubMed  CAS  Google Scholar 

  21. Grau MV, Baron JA, Sandler RS, Haile RW, Beach ML, Church TR, Heber D (2003) Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst 95:1765–1771

    PubMed  CAS  Google Scholar 

  22. Yonemaru K, Sakai H, Asaoka Y, Yanai T, Fukushi H, Watanabe K, Hirai K, Masegi T (2003) Cancer and the cyclooxygenase enzyme: Implications for the treatment and prevention. Am J Cancer 2: 27–55

    Google Scholar 

  23. Hollingsworth AB, Lerner MR, Lightfoot SA, Wilkerson KB, Hanas JS, McCay PB, Brackett DJ (1998) Prevention of DMBA-induced rat mammary carcinomas comparing leuprolide, oophorectomy, and tamoxifen. Breast Cancer Res Treat 47:63–70

    Article  PubMed  CAS  Google Scholar 

  24. Homma Y, Kaneko M, Kondo Y, Kawabe K, Kakizoe T (1997) Inhibition of rat prostate carcinogenesis by a 5-alpha-reductase inhibitor, FK143. J Natl Cancer Inst 89:803–807

    Article  PubMed  CAS  Google Scholar 

  25. Jordan VC (1976) Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 12: 419–424

    PubMed  CAS  Google Scholar 

  26. Jordan VC, Allen KE (1980) Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16:239–251

    PubMed  CAS  Google Scholar 

  27. Karkare MR, Clark TD, Glauert HP (1991) Effect of dietary calcium on colon carcinogenesis induced by a single injection of 1,2-dimethylhydrazine in rats. J Nutr 121:568–577

    PubMed  CAS  Google Scholar 

  28. Kobaek-Larsen M, Thorup I, Diederichsen A, Fenger C, Hoitinga MR (2000) Review of colorectal cancer and its metastases in rodent models: comparative aspects with those in humans. Comp Med 50:16–26

    PubMed  CAS  Google Scholar 

  29. Koo LC (1997) Diet and lung cancer 20+ years later: more questions than answers? Int J Cancer Suppl 10:22–29

    Google Scholar 

  30. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Trousset M, Attali P (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101: 635–639

    PubMed  CAS  Google Scholar 

  31. Lamb CA, Helguero LA, Fabris V, Lucas C, Molinolo AA, Lanari C (2003) Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma. Breast Cancer Res Treat 79:25–35

    Article  PubMed  CAS  Google Scholar 

  32. Liotta LA, Kohn EC, Petricoin EF (2001) Clinical proteomics: personalized molecular medicine. Jama 286:2211–2214

    Article  PubMed  CAS  Google Scholar 

  33. Lipkin M, Yang K, Edelmann W, Xue L, Fan K, Risio M, Newmark H, Kucherlapati R (1999) Preclinical mouse models for cancer chemoprevention studies. Ann N Y Acad Sci 889:14–19

    PubMed  CAS  Google Scholar 

  34. Lubet RA, Steele VE, Casebolt TL, Eto I, Kelloff GJ, Grubbs CJ (1994) Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis 15: 2775–2780

    PubMed  CAS  Google Scholar 

  35. Lubet RA, Steele VE, DeCoster R, Bowden C, You M, Juliana MM, Eto I, Kelloff GJ, Grubbs CJ (1998) Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model. Carcinogenesis 19:1345–1351

    Article  PubMed  CAS  Google Scholar 

  36. Lubet RA, Zhang Z, Wiseman RW, You M (2000) Use of p53 transgenic mice in the development of cancer models for multiple purposes. Exp Lung Res 26:581–593

    PubMed  CAS  Google Scholar 

  37. Maltoni C, Pinto C, Paladini G (1988) Project of experimental bioassays on chemoprevention agents performed at the Bologna Institute of Oncology: report on tamoxifen control of spontaneous mammary tumors on Sprague-Dawley rats. Cancer Invest 6:643–658

    PubMed  CAS  Google Scholar 

  38. Murakoshi M, Nishino H, Satomi Y, Takayasu J, Hasegawa T, Tokuda H, Iwashima A, Okuzumi J, Okabe H, Kitano H, et al (1992) Potent preventive action of alpha-carotene against carcinogenesis: spontaneous liver carcinogenesis and promoting stage of lung and skin carcinogenesis in mice are suppressed more effectively by alpha-carotene than by beta-carotene. Cancer Res 52:6583–6587

    PubMed  CAS  Google Scholar 

  39. Narisawa T, Fukaura Y, Takeba N, Nakai K (2002) Chemoprevention of N-methylnitrosourea-induced colon carcinogenesis by ursodeoxycholic acid-5-aminosalicylic acid conjugate in F344 rats. Jpn J Cancer Res 93:143–150

    PubMed  CAS  Google Scholar 

  40. Narisawa T, Kohno KI, Yamaguchi T, Takahashi T (1980) Chemoprevention of development of colonic adenomatosis and carcinomatosis with intrarectal dose of 5-FU on animal model. Cancer 45:439–443

    PubMed  CAS  Google Scholar 

  41. Narisawa T, Morotomi M, Fukaura Y, Hasebe M, Ito M, Aizawa R (1996) Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 87:798–804

    PubMed  CAS  Google Scholar 

  42. Narisawa T, Sato M, Tani M, Kudo T, Takahashi T, Goto A (1981) Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res 41:1954–1957

    PubMed  CAS  Google Scholar 

  43. Narisawa T, Satoh M, Sano M, Takahashi T (1983) Inhibition of initiation and promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroid anti-inflammatory agent indomethacin. Carcinogenesis 4:1225–1227

    PubMed  CAS  Google Scholar 

  44. Nettesheim P, Williams ML (1976) The influence of vitamin A on the susceptibility of the rat lung to 3-methylcholanthrene. Int J Cancer 17:351–357

    PubMed  CAS  Google Scholar 

  45. Nigro ND, Bull AW, Boyd ME (1986) Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil. J Natl Cancer Inst 77:1309–1313

    PubMed  CAS  Google Scholar 

  46. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK (1993) Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 80:1618–1619

    PubMed  CAS  Google Scholar 

  47. Obermueller-Jevic UC, Espiritu I, Corbacho AM, Cross CE, Witschi H (2002) Lung tumor development in mice exposed to tobacco smoke and fed beta-carotene diets. Toxicol Sci 69:23–29

    Article  PubMed  CAS  Google Scholar 

  48. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S (1996) Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150–1155

    Article  PubMed  CAS  Google Scholar 

  49. Osborne MP (1999) Chemoprevention of breast cancer. Surg Clin North Am 79:1207–1221

    Article  PubMed  CAS  Google Scholar 

  50. Pence BC, Buddingh F (1988) Inhibition of dietary fat-promoted colon carcinogenesis in rats by supplemental calcium or vitamin D3. Carcinogenesis 9:187–190

    PubMed  CAS  Google Scholar 

  51. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747–752

    Article  PubMed  CAS  Google Scholar 

  52. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R (2000) Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. Bmj 321:323–329

    Article  PubMed  CAS  Google Scholar 

  53. Pilat MJ, Kamradt JM, Pienta KJ (1998) Hormone resistance in prostate cancer. Cancer Metastasis Rev 17:373–381

    Article  PubMed  CAS  Google Scholar 

  54. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98–101

    PubMed  CAS  Google Scholar 

  55. Rao CV, Simi B, Raju J, Swamy, MV, Patlolla J M R, Steele VE, Kopelovich L, Reddy, BS (2004) ER, RXR, PPAR-?, HMG-CoA reductase and HDAC as molecular targets for the chemoprevention of colorectal cancer. Presented at Proc AACR, Orlando, Florida

    Google Scholar 

  56. Rao CV, Tokumo K, Rigotty J, Zang E, Kelloff G, Reddy BS (1991) Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 51: 4528–4534

    PubMed  CAS  Google Scholar 

  57. Ratko TA, Detrisac CJ, Dinger NM, Thomas CF, Kelloff GJ, Moon RC (1989) Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res 49:4472–4476

    PubMed  CAS  Google Scholar 

  58. Reddy BS (1998) Colon carcinogenesis models for chemoprevention studies. Hematol Oncol Clin North Am 12:963–973

    Article  PubMed  CAS  Google Scholar 

  59. Reddy BS (2000) The Fourth DeWitt S. Goodman lecture. Novel approaches to the prevention of colon cancer by nutritional manipulation and chemoprevention. Cancer Epidemiol Biomarkers Prev 9:239–247

    PubMed  CAS  Google Scholar 

  60. Reddy BS, Nayini J, Tokumo K, Rigotty J, Zang E, Kelloff G (1990) Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 50:2562–2568

    PubMed  CAS  Google Scholar 

  61. Richardson JL, Danley K, Mondrus GT, Deapen D, Mack T (1995) Adherence to screening examinations for colorectal cancer after diagnosis in a first-degree relative. Prev Med 24:166–170

    Article  PubMed  CAS  Google Scholar 

  62. Robert NJ (1997) Clinical efficacy of tamoxifen. Oncology (Huntingt) 11:15–20

    CAS  Google Scholar 

  63. Roberts RB, Arteaga CL, Threadgill DW (2004) Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. Cancer Cell 5:115–120

    Article  PubMed  CAS  Google Scholar 

  64. Robinson E, Kimmick GG, Muss HB (1996) Tamoxifen in postmenopausal women a safety perspective. Drugs Aging 8:329–337

    PubMed  CAS  Google Scholar 

  65. Russo IH, Russo J (1996) Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect 104:938–967

    PubMed  CAS  Google Scholar 

  66. Russo IH, Russo J (1998) Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3: 49–61

    Article  PubMed  CAS  Google Scholar 

  67. Russo J, Tay LK, Ciocca DR, Russo IH (1983) Molecular and cellular basis of the mammary gland susceptibility to carcinogenesis. Environ Health Perspect 49:185–199

    PubMed  CAS  Google Scholar 

  68. Saffiotti U, Montesano R, Sellakumar AR, Borg SA (1967) Experimental cancer of the lung. Inhibition by vitamin A of the induction of tracheobronchial squamous metaplasia and squamous cell tumors. Cancer 20:857–864

    PubMed  CAS  Google Scholar 

  69. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348: 883–890

    PubMed  CAS  Google Scholar 

  70. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD (2004) Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64:2270–2305

    Article  PubMed  CAS  Google Scholar 

  71. Sitrin MD, Halline AG, Abrahams C, Brasitus TA (1991) Dietary calcium and vitamin D modulate 1,2-dimethylhydrazine-induced colonic carcinogenesis in the rat. Cancer Res 51:5608–5613

    PubMed  CAS  Google Scholar 

  72. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869–10874

    Article  PubMed  CAS  Google Scholar 

  73. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952

    Article  PubMed  CAS  Google Scholar 

  74. Stoyanova RS, Clapper ML, Bellacosa A, Henske EP, Testa JR, Ross EA, Yeung AT, Nicolas E, Li Y-S, Linehan WM, Howard S, Campbell KS, Godwin AK, Boman B, Crowell JA, Kopelovich L, Knudson Jr. AG (2004) Altered gene expression patterns in phenotypically normal renal cells from individuals heterozygous for cancer mutations. Presented at AACR Annual meeting, Orlando, FL

    Google Scholar 

  75. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215–224

    Article  PubMed  CAS  Google Scholar 

  76. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani CM (2000) Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6:1024–1028

    PubMed  CAS  Google Scholar 

  77. Tsukamoto S, Akaza H, Imada S, Koiso K, Shirai T, Ideyama Y, Kudo M (1995) Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex. J Natl Cancer Inst 87:842–843

    PubMed  CAS  Google Scholar 

  78. Tsukamoto S, Akaza H, Onozawa M, Shirai T, Ideyama Y (1998) A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer 82:531–537

    PubMed  CAS  Google Scholar 

  79. Ueo H, Matsuoka H, Honda M, Inoue H, Takaki R, Akiyoshi T (1993) Chemopreventive effects of tamoxifen in ethyl methanesulphonate-induced rat mammary carcinogenesis. Cancer Lett 71:19–24

    Article  PubMed  CAS  Google Scholar 

  80. Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, D’Aiuto G, Lovison F, Gucciardo G, Muraca MG, Pizzichetta MA, Conforti S, Decensi A, Robertson C, Boyle P; Italian Tamoxifen Study Group (2003) Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 95:160–165

    PubMed  CAS  Google Scholar 

  81. Hawk ET, Umar A, Viner JL (2004) Cancer chemoprevention. In: Schottenfeld D, Fraumeni JF Jr (eds) Cancer epidemiology and prevention. Oxford University Press, New York

    Google Scholar 

  82. Wagenaar-Miller RA, Hanley G, Shattuck-Brandt R, DuBois RN, Bell RL, Matrisian LM, Morgan DW (2003) Cooperative effects of matrix metalloproteinase and cyclo-oxygenase-2 inhibition on intestinal adenoma reduction. Br J Cancer 88:1445–1452

    Article  PubMed  CAS  Google Scholar 

  83. Wargovich MJ, Allnutt D, Palmer C, Anaya P, Stephens LC (1990) Inhibition of the promotional phase of azoxymethane-induced colon carcinogenesis in the F344 rat by calcium lactate: effect of simulating two human nutrient density levels. Cancer Lett 53:17–25

    Article  PubMed  CAS  Google Scholar 

  84. Wargovich MJ, Chen CD, Jimenez A, Steele VE, Velasco M, Stephens LC, Price R, Gray K, Kelloff GJ (1996) Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol Biomarkers Prev 5:355–360

    PubMed  CAS  Google Scholar 

  85. Welsch CW, Goodrich-Smith M, Brown CK, Miglorie N, Clifton KH (1981) Effect of an estrogen antagonist (tamoxifen) on the initiation and progression of gamma-irradiation-induced mammary tumors in female Sprague-Dawley rats. Eur J Cancer Clin Oncol 17:1255–1258

    PubMed  CAS  Google Scholar 

  86. Wulfkuhle JD, Paweletz CP, Steeg PS, Petricoin EF 3rd, Liotta L (2003) Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv Exp Med Biol 532:59–68

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. GI and Other Cancers Research Group, National Cancer Institute, Suite 2141, 6130 Executive Boulevard, Bethesda, MD, 20892-7317, USA

    Ernest T. Hawk, Asad Umar, Ronald A. Lubet, Levy Kopelovich & Jaye L. Viner

Authors
  1. Ernest T. Hawk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Asad Umar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ronald A. Lubet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Levy Kopelovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jaye L. Viner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Zentrum für Tumordiagnostik und Prävention, Rorschacherstrasse 150, 9006, St. Gallen, Switzerland

    Hans-Jörg Senn  & Rudolf Morant  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Hawk, E.T., Umar, A., Lubet, R.A., Kopelovich, L., Viner, J.L. (2005). Can Animal Models Help Us Select Specific Compounds for Cancer Prevention Trials?. In: Senn, HJ., Morant, R. (eds) Tumor Prevention and Genetics III. Recent Results in Cancer Research, vol 166. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26980-0_6

Download citation

  • DOI: https://doi.org/10.1007/3-540-26980-0_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-22228-6

  • Online ISBN: 978-3-540-26980-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation